Loading organizations...
§ Private Profile · San Diego, CA, USA
Biopharmaceutical company developing small molecule therapeutics for hormone-driven cancers, focused on prostate and breast cancer.
Aragon Pharmaceuticals has raised $122.0M across 4 funding rounds.
Key people at Aragon Pharmaceuticals.
Aragon Pharmaceuticals has raised $122.0M in total across 4 funding rounds.
Aragon Pharmaceuticals is a San Diego, California-based biopharmaceutical company that develops small molecule therapeutics targeting hormone-driven cancers, such as castration-resistant prostate cancer and hormone-sensitive breast cancer. The enterprise advanced its lead compound, ARN-509, through Phase II clinical trials while raising over $80 million in venture capital financing across multiple equity rounds. The clinical-stage pipeline attracted significant institutional backing from prominent life science investors, including Venrock, OrbiMed, and Aisling Capital. In 2013, Johnson & Johnson acquired the business for $650 million in upfront cash and up to $350 million in contingent milestone payments, representing a total potential valuation of $1 billion. Immediately prior to the acquisition, the entity spun out its remaining breast cancer research assets into a newly formed independent corporation called Seragon Pharmaceuticals. Aragon Pharmaceuticals was founded in 2009 by Charles Sawyers, Michael Jung, and Richard Heyman.
Aragon Pharmaceuticals has raised $122.0M across 4 funding rounds. Most recently, it raised $50.0M Series D in October 2012.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2012 | $50M Series D | — | Aisling Capital, General Atlantic, OrbiMed, The Column Group, Aisling Capital, Topspin Fund | Announced |
| Mar 6, 2012 | $42M Series C | LEO Guthart | Aisling Capital, OrbiMed, The Column Group | Announced |
| Apr 1, 2010 | $22M Series B | — | Aisling Capital, General Atlantic, OrbiMed, The Column Group, Brett Zbar | Announced |
| May 1, 2009 | $8M Series A | — | OrbiMed, The Column Group | Announced |
Aragon Pharmaceuticals has raised $122.0M in total across 4 funding rounds.
Aragon Pharmaceuticals's investors include Aisling Capital, General Atlantic, OrbiMed, The Column Group, Topspin Fund, Leo Guthart, Brett Zbar.
Key people at Aragon Pharmaceuticals.
Aragon Pharmaceuticals was a biotechnology company specializing in small-molecule drug discovery for hormonally-driven cancers, particularly those resistant to first-generation antihormonal therapies, such as castration-resistant prostate cancer and breast cancer[1][2][3]. Its lead product, ARN-509 (later developed as apalutamide), targeted androgen receptor signaling inhibition and advanced to Phase II/III trials, addressing unmet needs in advanced prostate cancer treatment where existing options were ineffective or toxic[1][4][5][6]. The company served oncology patients and physicians, solving the problem of hormone therapy resistance by developing second-generation agents that block and degrade hormone receptors, with potential expansion to early-stage prostate, breast, endometrial, and ovarian cancers[1][5]. Aragon was acquired by Johnson & Johnson in August 2013 for $650 million upfront plus up to $350 million in milestones, totaling potentially $1 billion, after spinning off its estrogen receptor program to Seragon Pharmaceuticals[1][4][5].
Aragon Pharmaceuticals emerged from pioneering research by Charles Sawyers on molecular mechanisms of drug resistance in hormone-driven cancers, building on his prior work that contributed to imatinib (Gleevec) for leukemia[3][5]. Founded around 2007-2008 (exact year not specified in sources), it was co-founded by key figures including CEO Richard A. Heyman, PhD, who previously served as Chief Scientific Officer at X-Ceptor Therapeutics (acquired by Exelixis in 2004) and held research leadership at Ligand Pharmaceuticals, where he advanced FDA-approved cancer retinoids[3]. Other notable team members included executives with deep experience at Amgen, Pfizer, IDEC (Biogen Idec), and Exelixis, bringing expertise in drug development, commercialization, and business deals like Rituxan and out-licensing to Genentech[3]. Early traction came from advancing ARN-509 into Phase I/II trials for progressive castration-resistant prostate cancer, culminating in the high-value J&J acquisition that validated its science[1][4][5].
Aragon rode the wave of precision oncology in the late 2000s-early 2010s, focusing on endocrine-driven cancers amid rising demand for therapies targeting resistance mechanisms in prostate and breast cancers[1][5]. Timing was ideal as first-line antihormonals like abiraterone (Zytiga, from J&J) gained traction, but resistance limited options—Aragon's second-generation inhibitors filled this gap, influencing J&J's oncology dominance[4]. Market forces like aging populations, increasing cancer incidence, and biotech M&A booms favored its model, with the $1 billion deal underscoring investor appetite for hormone receptor innovations[5]. Post-acquisition, Aragon's tech bolstered Janssen's pipeline, contributing to apalutamide's approval and shaping competitive dynamics against therapies like enzalutamide, while its Seragon spin-off (later acquired by Gilead) expanded estrogen receptor degrader ecosystems[5][6].
Aragon's legacy endures through apalutamide, a cornerstone in prostate cancer treatment integrated into J&J's portfolio, with ongoing Phase 3 expansions and combinations addressing metastatic disease[6]. Next steps involve Janssen leveraging it in broader oncology combos amid trends like ADCs, PSMA-targeted therapies, and resistance-overcoming bispecifics in a $10B+ prostate market[1][6]. As biotech consolidates, Aragon exemplifies how targeted biotech exits amplify impact, evolving from startup innovator to global standard-setter in hormonally-driven cancers—reinforcing that niche resistance-breakers drive enduring ecosystem value.
